Differential Expression of FGFRs Signaling Pathway Components in Bladder Cancer: A Step Toward Personalized Medicine

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Aberrant fibroblast growth factor receptor (FGFR) signaling is implicated in various cancers, positioning FGFR inhibitors as potential therapeutic agents.
• Inter-individual variations in drug response underscore the need for personalized medicine approaches, particularly in diverse populations.
• Understanding specific FGFR expression patterns in distinct ethnic groups is crucial for targeted cancer therapies.

Purpose of the Study:

• To investigate the expression levels of FGFR1 and FGFR3 in Iranian patients with bladder cancer (BC).
• To correlate FGFR1 and FGFR3 expression with clinicopathological features of BC in this population.
• To explore the potential of FGFRs as therapeutic targets in Iranian BC patients.

Main Methods:

• A pilot study involving 50 Iranian BC patients.
• Paired tumor and adjacent non-tumor tissue samples were collected.
• Messenger RNA (mRNA) expression of FGFR1 and FGFR3 was quantified using real-time polymerase chain reaction (real-time PCR).

Main Results:

• FGFR3 mRNA expression was significantly higher in tumor tissues compared to normal tissues (p = 0.007), irrespective of tumor stage or grade.
• FGFR3 overexpression correlated with a history of cigarette smoking (p = 0.037) and family cancer history (p = 0.004).
• FGFR1 mRNA expression was generally decreased, with notably lower levels in high-grade tumors (p = 0.047) and higher levels in low-grade tumors.

Conclusions:

• Distinct expression patterns of FGFR1 and FGFR3 were observed in Iranian BC patients, differing significantly based on tumor stage and grade.
• These specific expression profiles suggest that FGFR1 and FGFR3 may hold value as biomarkers and targets for personalized interventional studies in BC.
• Further validation with larger sample sizes is warranted to confirm these findings and their clinical implications.